Results 121 to 130 of about 2,606,163 (178)

MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). [PDF]

Br J Clin Pharmacol
McDermott JH, Hilton S, Dello Russo C, Booth N, Drysdale S, Howard P, Hughes S, Chakraborty M, McDevitt H, Alston C, Desai M, Beadsworth M, Reynolds A, Min S, Payne K, Pirmohamed M, Newman WG.   +16 more
europepmc   +1 more source

Otoprotective effect of MnTBAP in cisplatin-induced hearing loss. [PDF]

PLoS One
Mehmood S, Bhatia P, Jamesdaniel S.
europepmc   +1 more source

Tobramycin pharmacokinetic and pharmacodynamic targets in people with cystic fibrosis. [PDF]

Br J Clin Pharmacol
Harwood KH, Bannister S, Duffull S, Martinez A, Ranganathan S, Shanthikumar S, Gwee A.   +6 more
europepmc   +1 more source

Early Detection of Ototoxicity Using Serial Mobile Audiometry, Otoacoustic Emissions Testing, and Inner Ear Biomarker Measurement in Patients Receiving Platinum-Based Chemotherapy Treatment: It is Feasible to Implement in a National Health Service (NHS) Cancer Ambulatory Care Setting. [PDF]

Otol Neurotol
Mehta N, Awad A, Forbes M, Iliadou E, Katiri R, Ferdous T, Lowe H, Ensell L, Alifrangis C, Schilder AGM, Windsor R.   +10 more
europepmc   +1 more source

Progressive Sensorineural Hearing Loss Following Cisplatin Chemotherapy: Mechanisms Underlying Cochlear Retention and Long-Term Ototoxicity. [PDF]

Pharmaceuticals (Basel)
Ruggiero A, Picciotti PM, Mastrangelo S, Romano A, Talloa D, Galli J, Attinà G.   +6 more
europepmc   +1 more source

Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey. [PDF]

Cancer Med
Lacey C, Clark K, Debacker JR, Stuehm H, Hungerford M, Milnes T, Johansson K, Mannino R, Graff JN, Konrad-Martin D.   +9 more
europepmc   +1 more source

From historical dosing to precision dosing: Modernising tobramycin monitoring in people with cystic fibrosis. [PDF]

Eur J Clin Pharmacol
Johnson E, Williams M, Henderson D, Riddles T, Reid D, Smith D, Burke A, Evans IES.   +7 more
europepmc   +1 more source

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network. [PDF]

Ear Hear
Streefkerk N, Geller JI, Knight K, Ansari M, Papadakis V, Calaminus G, Masroor A, Huitema ADR, Pasqualini C, Rutkowski S, Bouffet E, Am Zehnhoff-Dinnesen A, Caniza M, van de Wetering MD, Delano P, Rajput KM, Weerdenburg H, Frazier AL, Hoetink AE, van Grotel M, Gaspar N, Shaikh F, Fresneau B, O'Neill AF, Veal GJ, Sullivan M, Brock PR, van den Heuvel-Eibrink MM.   +27 more
europepmc   +1 more source

Progressive Hearing Loss in Childhood - A Prognostic Factor Systematic Review.

Audiol Neurootol
Dempsey J, Walker NR, Lawrence M, Shields C, Martin GP, Kluk K, Bruce I, Nichani JR.   +7 more
europepmc   +1 more source

Therapeutic Drug Monitoring and Adverse Drug Reactions: From Signal Detection to Prevention. [PDF]

Pharmaceuticals (Basel)
Algharably E, Gundert-Remy U.
europepmc   +1 more source